Member Info for PC01

Well I have tried to add reasonable size today at 2.85 and got 1000 shares...weird...have left an order to buy a further 10,000 there...

I think u have nailed it there dutch...what puzzles me is why the $25mm number freely bandied about to me and therefore I assume all the other investors wasn't given more air-time...remember, he was astonished when I asked if the trading statement was an implied profit-warning, given problems with Spire...so I have to assume (dangerous!) that meet on bones will be supplied soon.

I think we live in a world of instant gratification. I buy XXX shares of ABC company and I want them to double, now! I could not be happier if Tosca think they way for them to recoup and then make on their investment in SLE is a 5yr work out period...if that gets the SP back to £2 then happy days...I had a long look at Serica, no rush...huge overhang of shares...reckon one for the radar once it breaks 25p! back to SLE....by my reckoning they have received a further $36mm this year....i do hope we get one more tender before the company thinks it has better uses for the excess cash!

i do so hope you waited for SXX - seems like no rush there at all with today's huge refi package....re SLE (for that is what this BB page is about), am I alone in thinking its been a bit quiet in terms of newsflow...i mean, we've had nothing of note really this year except for the tender offer when there should be 'quite alot' happening....think I may need to buy back some of those I sold at 46p...

Just take a step back...this stock was trading at 50p in February. It has since risen 6x in 10 weeks on decent trial news and a chinese deal. Technically, it is massively overbought - the 20 day moving average is at £2.20 and the 50 day at £1.30 confirming how far we have moved. At some stage, we will have to have a pause as stocks very rarely / almost never go from X to infinty in a straight line. Days like today and as Ms Tulip said when we were c £2.30 are very healthy for the stock. The stock will reach its final destination in time, as the company progresses from a research co to one that has a product, whereupon it would be almost impossible to believe it won't get taken out. But that remains a distance off. So my advice remains the same. No guarantees, do not invest what you can't afford to lose - indeed if you were lucky / skilfull enough to get in at the lows, take some profit so your 'in-cost' is lowered. And when news comes out you may feel happier adding to it at £4 or £5 or £6 as the investment case becomes clearer. But truly do not worry when someone takes a few chips off the table after a move like this, its entirely normal and extremely healthy!
GLA.

HI
http://www.reneuron.com/investors/major-shareholdings/

45% in 2 hands.

36.63% of the issued share capital is not in public hands.

Directors 1.32%.

So 80%+ in large institutional / directors or non-public hands. Hope that helps.

Having worked at one of these brokers in the past you are right to be cautious about any in-house broker upgrade...I think it’s just Edison n Stifel that publish research on Reneuron. I do not believe they are paid £££ directly to write the research but they will be paid when there is a capital market event - eg equity raising / debt raising or any corporate advice / finance. You have to remember these days of Mifid 2 mean everything has to be above board and strict Chinese walls exist between research and corporate finance.
Sorry to bore on a Saturday morning! That’s not to say by the way that this weeks news was another spectacular step in the right direction! Still cheap at £100mm which barely covers cash in bank and the proceeds from the Fosun deal!

Stifel research - pretty much what all has been said here - concludes with :
Plenty of further potential upside; reiterate Buy. Our TP of 690p, based on an rNPV of both the hRPC and CTX (chronic stroke) programmes, is still built on what we consider to be relatively conservative expectations. For the hRPC programme, we estimate peak US sales of $900m, but still assume a launch in 2025, which could be brought forward should the next step be a single pivotal trial, and apply a 20% probability of success, which could be argued is too modest in the context of the clinical data presented thus far. We also have a conservative drug price point at $150,000 vs $850,000 for the Luxturna gene therapy used in a small subset of RP patients.

For every buyer there was a seller...some sizeable trades seem to have gone thru tho ...that said, its hard to imagine the B-o-D buying shares as they have been and were allowed and then seen the news drop the other way...and it most certainly is not 'too damn late'...the market cap is touching £100mm. It has £40mm in the bank, its signed a huge deal in China and it has now progressed beyond stage 2 in a clinical trial where some on this board were suggesting the treatment for blindness runs into the 100s of thousand. £3.10 seems a lot to pay vs the £2.60 close yesterday or the 50p you could have bought at a few months ago. But in my opinion it far undervalues the 'POTENTIAL'...

Dear OS - I have enjoyed your glass 1/2 empty approach over the months we've 'known' each other on this board...indeed you have always been the 'show me the money' type which is refreshing however a few things re your post :
It is utter nonsense to suggest any company is run for the benefit of private vs institutional shareholders...Kongats can have ABSOLUTELY no say in who buys or sells CPX shares (except for directors in blackout periods etc)...to suggest anyone runs any company cash rich or otherwise for the benefit of any particular class of shareholder is misguided in the extreme. De facto, why does it matter if anyone owns 0.1%, 1% or 5% of a company. When news comes and a decision to sell is taken, it simply cannot matter who owns how many. because if the news is sh*t, then 100 small shareholders who each own 0.1% might decide to exit in the same way that a fund owning 10% might...
secondly - IP...as per my msg the other day, TDK was signed up directly because it had infringed patent. Just think on that. Ioxus, he said, woul pay out many times the $70k litigation costs so far. Again I therefore disagree with you.
Lastly - 'supposedly' in line 1...not sure what you mean by that? Cash reserves are 3x what they were at end of FY2017, when the SP spent most of the year trading 2-4x higher than where we are now.
I believe You have been 100% correct in your assessment of CPX so far, but I think your comments today are worthy of correction.

2 things - no stock about, have tried to buy this am and can't get any...and don't forget the presentation this afternoon....

Johndr65, if u can log on here...you will see Rene share chat, then beside it trades and then beside it RNS....

And a market cap of 'just' £83million at last night's close...its so easy these day's to get carried away with hopes and expectations, but it's hard to see this SP not doubling from here in short order. To try and get a little less excited we are still in the very early stages, I get that, but even at £150mm say we are chicken feed for the large pharma firms...its been a very long time coming and I'm not ready to hand my shares back just as it starts to become fun owning them!
Good luck one and all...

I know nothing about Sirius Minerals except it seems to get tipped every quarter in all the tip sheets but never seems to be able to hold onto any gains! i think a few of us here would think that SLE has masses of potential over the coming few quarters for the SP to have a gentle drift higher....especially with OIL daring to disobey the Great Trump and go higher!

Its a lovely thought but personally I think shareholders will want verification and numbers to support this optimism. We found long term technical support at 3.85 (I find it amazing how these chart points work) but sadly there are a lot of dead bodies (as I call them) between here and the 8.5p placing. First major resistance is 5.82 (May 2017 low) and then 7.5p will prove major resistance. Interestingly, the 200 daily moving average lies around the 8.5p placing, and only when (if??) we break that level will we reach the sunlit uplands.
In my opinion, it actually won't take much to get back there, a couple of large auto contracts and growing confidence of break even in 2020....but it needs to get a move on to reach my target of 20p by the end of the year!

Well it would be nice, wouldn't it? There is a mountain of news to come over the next few weeks and months to come with which we can then draw up a better understanding of the likely destination of the share price. Seems like the overhang of stock pretty much gone. I'd like a better understanding of cashflows due from the Eroton investment given where oil is currently trading. I'm not sure a 20% increase in the price of oil has in anyway been priced into our share price! With debt repayments on top, I'm still very much of the view of another tender, given that the company and more pertinently its largest shareholder feel the shares are underpriced at 46p....

As I hope i said (there's been a lot of comments!) there was no inside information given. The one point I have heard mention time and again is AK's fear of misleading shareholders with hopes rather than facts - the answer to my question 'are you where you hoped you would be?' was met with a categorical no...eg plenty are the times that the company has felt on the edge of star dust only to have failed to have realised its potential, either through its own short-comings or its customers. I did also say that the company will not make a profit this year, unless a large order lands...the hope remains for Q1/Q2 2020, a la Allenby research.
The SP is low, but shareholder confidence is likewise...a few well timed RNS' confirming the pipeline and indeed receipt of hard $$ will do much to cause the SP to re-rate...

What do you mean 'it just did not happen?'...I asked at the end of the meeting if any information received was confidential and was told no...and before you suggest I am making things up, there was another present at the meeting who reads this board but who's confidentiality I will keep...who asked to come along as an investor with whom we shot the breeze over a coffee...
To reiterate there is a pipeline of orders worth A$25mm...that have been received...as per the first line of my post...the company will not breakeven this year so don't for a second think they are all for fulfilling today...and who said automotive? I mentioned Roche's insulin order...and the presentation says :
4 types of auto order - 1 x global car manufacturer (dashboard), 1 x Tier 1 OEM (windscreen), 1 x Tier1/2 OEM (key fob) and 1 x Tier 1 OEM door locking\
4 types of industrial orders including ABB's pump controller, Itron smartmeters, energy harvesting and construction equipment,
4 types of tracking equipment including Intermec scanners, caretech patient scanners
and then healthcare - which Kongats was keen to imply was 2nd to auto and includes Roche's diabetic pump and spire health tag.
You can truly use of this information as u see fit, but please don't irritate me by suggesting I am telling untruths or that there is deliberate misleading going on. And read my post this morning - this company remain loss making and is not for everyone.
Right that's me done, easter eggs to buy, golf balls to hit have a good weekend all.

Hi Annie ...AUD$25mm is Australian dollars (CPX being an Australian company in case you were not sure) 25 million of orders in the pipeline...physical orders received not inquiries thereof...
2 things came out of the posts to my message...the over riding sense of relief from many that it seems we are not invested in a pup and then the reality that someone thinks CPX at 4p is worth buying a decent stake in (much better timed than I managed!)...I just want to say one thing...my witterings are the thoughts of myself...its bad enough losing your own money but I would hope no one invests on the back of my comments. I have said on countless times that i own an outsized amount of this company's shares...and yes, may even add to that over the next few days...but to one and all, this is not an investment for anyone who cannot afford to lose money. It doesn't make money nor does it expect to do so for some time yet, doesn't pay a dividend, it doesn't tick any boxes that normal, sane investors look for. What is does offer, in my very inexpert opinion, is the possibility of an outsized return if it can get all its ducks in a row. And by outsized i mean a minimum of 5-10x what it's worth here.
Be interesting to see how the stock trades today, good bounce from the 3.85p support (from the lows in 2016). If the big seller has been taken out, then it would look technically quite good on a break and hold above 5 then 5.8p.

Without wishing to point out the blindingly obvious...there has to have been a big sale...otherwise someone buying 3.5% of the company would not have got the stock at 4p...what I hope is it takes the b%stard out!
re patent case question...yes very optimistic...thinks Ioxus will settle for several times the cost of patent defense.